PT  - JOURNAL ARTICLE
AU  - Innes, Stuart C.
AU  - Joe, Dorothy K.
AU  - Cikurel, Katia
AU  - Lavrador, José P.
AU  - Vergani, Francesco
AU  - Bhangoo, Ranjeev
AU  - Ashkan, Keyoumars
AU  - Finnerty, Gerald T.
TI  - Consequences of Acute Presentations of Functional Neurological Disorders in Neuro-oncology patients: Case Series and Systematic Review
AID  - 10.1101/2024.11.14.24317315
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.14.24317315
4099  - http://medrxiv.org/content/early/2024/11/15/2024.11.14.24317315.short
4100  - http://medrxiv.org/content/early/2024/11/15/2024.11.14.24317315.full
AB  - Objective New neurological symptoms in neuro-oncology patients are usually attributed to the tumour or its treatment. A diagnosis of functional neurological disorder (FND) is often only considered when investigations do not reveal a cause and medical management fails. Here, we investigate the consequences of acute FND in neuro-oncology patients.Methods We performed a single-centre retrospective case study of adult neuro-oncology patients with an intracranial tumour who presented acutely with FND. Data recorded were: tumour type, investigations, adverse life events, medical interventions and outcomes. This was combined with a systematic literature review of articles in English peer-reviewed journals on adults with brain or meningeal tumours and concomitant FND.Results Ten patients met our study criteria. Six had functional seizures, two had functional hemiparesis and two had functional speech disorders. FND symptoms started: prior to tumour diagnosis in three patients; between diagnosis and treatment in four; and after treatment commenced in three patients. Two patients were thrombolysed for presumed stroke. Three patients had their tumour surgery or chemoradiotherapy delayed. Diagnosis and management of FND enabled tumour treatment to restart. The systematic review identified 37 patients. 33 had functional seizures and four had motor FND. All FND diagnoses except one started after tumour treatment commenced.Conclusion Acute FND may lead to unnecessary medical interventions and disrupt tumour treatment. Although acute FND improved with diagnosis and explanation, many neuro-oncology patients require a multi-disciplinary tumour-FND pathway to manage their FND, prevent acute FND symptoms becoming chronic and to avoid delays to tumour treatment.What is already known on this topic Case reports have documented functional neurological disorders (FND) in brain tumour patients, but almost invariably after their tumour treatment has commenced.What this study adds FND can present acutely at any stage of the brain tumour illness and may result in inappropriate interventions and/or treatment. Tumour treatment may be delayed.How this study might affect research, practice or policy Brain tumour patients require a multi-disciplinary FND pathway, not only to manage their FND symptoms, but to prevent delays to tumour treatment, which is proscribed by government guidance on timely treatment of cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr Stuart Innes, Academic Clinical Fellow (ACF-2022-17-010), is funded by the NIHR for this research project. The funding bodies had no role in the conduct of the study. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (Neurology) at King's College Hospital NHS Foundation Trust gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript